{"filing":{"accession_number":"0001193125-26-336762","cik":"0001768446","ticker":"CLYM","company_name":"Climb Bio, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"clym-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526336762/clym-20260806.htm"},"events":[{"id":25551,"run_id":23193,"accession_number":"0001193125-26-336762","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Climb Bio issued a press release on August 6, 2026 announcing financial results for the quarter ended June 30, 2026, including condensed consolidated balance sheets and statements of operations. The disclosure includes cash position ($239.2 million), R\u0026D expenses ($9.7 million), G\u0026A expenses ($5.6 million), net loss ($13.5 million), and net loss per share ($0.18), along with business updates on clinical pipeline progress. This is a standard quarterly earnings release with financial statements attached as Exhibit 99.1, typical of Item 2.02 disclosures.","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26418,"accession_number":"0001193125-26-336762","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Climb Bio issued a press release on August 6, 2026 announcing financial results for the quarter ended June 30, 2026, including condensed consolidated balance sheets and statements of operations. The disclosure includes cash position ($239.2 million), R\u0026D expenses ($9.7 million), G\u0026A expenses ($5.6 million), net loss ($13.5 million), and net loss per share ($0.18), along with business updates on clinical pipeline progress. This is a standard quarterly earnings release with financial statements attached as Exhibit 99.1, typical of Item 2.02 disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:54:21.933704+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26418,"accession_number":"0001193125-26-336762","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Climb Bio issued a press release on August 6, 2026 announcing financial results for the quarter ended June 30, 2026, including condensed consolidated balance sheets and statements of operations. The disclosure includes cash position ($239.2 million), R\u0026D expenses ($9.7 million), G\u0026A expenses ($5.6 million), net loss ($13.5 million), and net loss per share ($0.18), along with business updates on clinical pipeline progress. This is a standard quarterly earnings release with financial statements attached as Exhibit 99.1, typical of Item 2.02 disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:54:21.933704+00:00","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-08-06"}]}